TY - JOUR
T1 - The clinical outcome study for dysferlinopathy an international multicenter study
AU - Harris, Elizabeth
AU - Bladen, Catherine L.
AU - Mayhew, Anna
AU - James, Meredith
AU - Bettinson, Karen
AU - Moore, Ursula
AU - Smith, Fiona E.
AU - Rufibach, Laura
AU - Cnaan, Avital
AU - Goebel, Diana X.Bharucha
AU - Blamire, Andrew M.
AU - Bravver, Elena
AU - Carlier, Pierre G.
AU - Day, John W.
AU - Díaz-Manera, Jordi
AU - Eagle, Michelle
AU - Grieben, Ulrike
AU - Harms, Matthew
AU - Jones, Kristi J.
AU - Lochmüller, Hanns
AU - Mendell, Jerry R.
AU - Yoshimura, Madoka Mori
AU - Paradas, Carmen
AU - Pegoraro, Elena
AU - Pestronk, Alan
AU - SalortCampana, Emmanuelle
AU - Schreiber-Katz, Olivia
AU - Semplicini, Claudio
AU - Spuler, Simone
AU - Stojkovic, Tanya
AU - Straub, Volker
AU - Takeda, Shinich
AU - Rocha, Carolina Tesi
AU - Walter, M. C.
AU - Bushby, Kate
N1 - Publisher Copyright:
© 2016 American Academy of Neurology.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Objective: To describe the baseline clinical and functional characteristics of an international cohort of 193 patients with dysferlinopathy. Methods: The Clinical Outcome Study for dysferlinopathy (COS) is an international multicenter study of this disease, evaluating patients with genetically confirmed dysferlinopathy over 3 years. We present a cross-sectional analysis of 193 patients derived from their baseline clinical and functional assessments. Results: There is a high degree of variability in disease onset, pattern of weakness, and rate of progression. No factor, such as mutation class, protein expression, or age at onset, accounted for this variability. Among patients with clinical diagnoses of Miyoshi myopathy or limb-girdle muscular dystrophy, clinical presentation and examination was not strikingly different. Respiratory impairment and cardiac dysfunction were observed in a minority of patients. A substantial delay in diagnosis was previously common but has been steadily reducing, suggesting increasing awareness of dysferlinopathies. Conclusions: These findings highlight crucial issues to be addressed for both optimizing clinical care and planning therapeutic trials in dysferlinopathy. This ongoing longitudinal study will provide an opportunity to further understand patterns and variability in disease progression and form the basis for trial design.
AB - Objective: To describe the baseline clinical and functional characteristics of an international cohort of 193 patients with dysferlinopathy. Methods: The Clinical Outcome Study for dysferlinopathy (COS) is an international multicenter study of this disease, evaluating patients with genetically confirmed dysferlinopathy over 3 years. We present a cross-sectional analysis of 193 patients derived from their baseline clinical and functional assessments. Results: There is a high degree of variability in disease onset, pattern of weakness, and rate of progression. No factor, such as mutation class, protein expression, or age at onset, accounted for this variability. Among patients with clinical diagnoses of Miyoshi myopathy or limb-girdle muscular dystrophy, clinical presentation and examination was not strikingly different. Respiratory impairment and cardiac dysfunction were observed in a minority of patients. A substantial delay in diagnosis was previously common but has been steadily reducing, suggesting increasing awareness of dysferlinopathies. Conclusions: These findings highlight crucial issues to be addressed for both optimizing clinical care and planning therapeutic trials in dysferlinopathy. This ongoing longitudinal study will provide an opportunity to further understand patterns and variability in disease progression and form the basis for trial design.
UR - http://www.scopus.com/inward/record.url?scp=85007275504&partnerID=8YFLogxK
U2 - 10.1212/NXG.0000000000000089
DO - 10.1212/NXG.0000000000000089
M3 - Article
C2 - 27602406
AN - SCOPUS:85007275504
SN - 2376-7839
VL - 2
JO - Neurology: Genetics
JF - Neurology: Genetics
IS - 4
M1 - e89
ER -